ASH 2018 | Impact of MRD in FLT3+ AML: results from CHRYSALIS

Alexander Perl

Alexander Perl, MD, of the University of Pennsylvania, Philadelphia, PA, discusses the results of the Phase I/II CHRYSALIS study (NCT02014558), specifically the impact of peripheral blood measurable residual disease (MRD) on overall survival following treatment with gilteritinib, the first single-agent therapy for relapsed/refractory acute myeloid leukemia (AML) patients with FLT3 mutations. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Perl suggests a potential association between an MRD negative status and longer survival in patients with FLT3-mutated AML.

Share this video